{
    "nct_id": "NCT02946034",
    "official_title": "Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen",
    "inclusion_criteria": "1. Male or female ≥ 18 year of age\n2. HCV genotype 1 ≥ 1000 IU/mL\n3. 6. Estimated glomerular filtration rate 15-45mL/min/1.73m2 as estimated by CKD-Epi equation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Pregnant or lactating females\n2. Uncontrolled depression or psychiatric disease\n3. History or presence of any form of cancer within 3 years of enrollment\n4. Experiencing life-threatening cryoglobulinemic vasculitis requiring initiation of rituximab, steroids or plasmapheresis.\n5. Uncontrolled cardiovascular or pulmonary disease\n6. Experiencing symptoms attributed to uremia\n7. Anticipated need to begin renal replacement therapy in the next 6 months\n8. History of kidney transplant",
    "miscellaneous_criteria": ""
}